A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
KaliVir Immunotherapeutics
Centre Oscar Lambret
Dana-Farber Cancer Institute
Psyence Australia Pty Ltd
Dana-Farber Cancer Institute
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
Second Life Therapeutics
Novartis
University of Pittsburgh
Degron Therapeutics Co.
University of Aarhus
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Hadassah Medical Organization
Washington University School of Medicine
Fudan University
Sensei Biotherapeutics, Inc.
Institut Claudius Regaud
Genentech, Inc.
DEKA Biosciences
Columbia University
Henan Cancer Hospital
Dana-Farber Cancer Institute
Inhibrx Biosciences, Inc
Hospices Civils de Lyon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
European Organisation for Research and Treatment of Cancer - EORTC
Second Affiliated Hospital of Guangzhou Medical University
Cedars-Sinai Medical Center
Celldex Therapeutics
AO GENERIUM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shanghai Yunying Medical Technology
Kineta Inc.
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Rush University Medical Center
Imperial College London
Roswell Park Cancer Institute
University Hospital, Clermont-Ferrand
Pfizer
National Institutes of Health Clinical Center (CC)
Brown University
Novartis